FindTrial
Sign In

CRC01

BIOLOGICAL2 trials

Sponsors

Curocell Inc.

Conditions

ALL (Acute B-Lymphoblastic Leukemia)Diffuse Large B-cell Lymphoma (DLBCL)High-grade B-cell LymphomaLupus NephritisLupus Nephritis (LN)Primary Mediastinal Large B-Cell Lymphoma (PMBCL)Refractory Large B-cell LymphomaRelapsed Large B-cell Lymphoma

Phase 1

Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients
RecruitingNCT04836507
Curocell Inc.ALL (Acute B-Lymphoblastic Leukemia), Diffuse Large B-cell Lymphoma (DLBCL), High-grade B-cell Lymphoma +4
Start: 2021-03-02End: 2030-09-26Target: 91Updated: 2026-07-01
Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus Erythematosus
Not yet recruitingNCT07364396
Curocell Inc.Lupus Nephritis, Lupus Nephritis (LN), SLE +1
Start: 2026-02-01End: 2030-06-01Target: 39Updated: 2026-01-23

Related Papers

Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01).
2026-06-12
Phase 1/2 study of anbalcabtagene autoleucel, novel anti-CD19 CAR-T cell therapy with dual silencing of PD-1 and TIGIT in relapsed or refractory large B-cell lymphoma.
Journal of Clinical Oncology2022-06-017 citations
S214: PHASE 1/2 STUDY OF ANBAL-CEL, NOVEL ANTI-CD19 CAR-T THERAPY WITH DUAL SILENCING OF PD-1 AND TIGIT IN RELAPSED OR REFRACTORY LARGE B CELL LYMPHOMA
HemaSphere2022-06-011 citations
Characteristics of CRC01, an investigational CD19 CAR-T product with PD-1 and TIGIT genes silenced by shRNAs.
Journal of Clinical Oncology2022-06-01
PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells.
2021-10-0862 citations